The emergence of biologic therapies for the management of asthma has been a
revolutionary change in our capacity to manage this disease. Since the launch of …

The existence of eosinophils was documented histopathologically in the first half of the 19th
century. However, the term “eosinophils” was first used by Paul Ehrlich in 1878. Since their …

Asthma, one of the most common lung diseases, remains a serious global health problem.
Currently there is still an urgent need for effective and safe therapies against severe asthma …

Several current guidelines/strategies outline a treatment approach to asthma, which
primarily consider the goals of improving lung function and quality of life and reducing …

Background There are now many biological therapies to treat severe asthma. To assess
which work best for which patient, we need to develop definitions of response. This narrative …

Introduction Monoclonal antibodies (mAbs) should be administered by inhalation rather than
parenterally to improve their efficiency in lung diseases. However, the pulmonary …

Thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine, acts as a key
mediator in airway inflammation and modulates the function of multiple cell types, including …

Background A significant breakthrough has been made in treating severe asthma, with the
recognition of various asthma phenotypes and an updated management guideline. Type 2 …

Background: Pandemic of COVID-19 has gathered up the surrounding respiratory diseases
such as asthma. The need to combat asthma is an unanswerable question nowadays and …

Background: Dupilumab, a human monoclonal anti-interleukin (IL)-4Ra antibody blocks the
shared receptor component of IL-4 and IL-13, drivers of type 2 inflammation. Dupilumab is …